Evidence map›Paper›PMID 36249875›Full record

ArticleACS catalysis2022

How a 10-

Joshua N Whitehead, Nicole G H Leferink, Gajendar Komati Reddy, Colin W Levy, Sam Hay, Eriko Takano, Nigel S Scrutton

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS catalysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Joshua N WhiteheadManchester Institute of Biotechnology, Department of Chemistry, The University of Manchester, Manchester M1 7DN, U.K.ORCID https://orcid.org/0000-0001-9978-4631
Nicole G H LeferinkFuture Biomanufacturing Research Hub (FBRH), Manchester Institute of Biotechnology, Department of Chemistry, The University of Manchester, Manchester M1 7DN, U.K.
Gajendar Komati ReddyManchester Institute of Biotechnology, Department of Chemistry, The University of Manchester, Manchester M1 7DN, U.K.
Colin W LevyManchester Institute of Biotechnology, Department of Chemistry, The University of Manchester, Manchester M1 7DN, U.K.
Sam HayManchester Institute of Biotechnology, Department of Chemistry, The University of Manchester, Manchester M1 7DN, U.K.ORCID https://orcid.org/0000-0003-3274-0938
Eriko TakanoManchester Institute of Biotechnology, Department of Chemistry, The University of Manchester, Manchester M1 7DN, U.K.
Nigel S ScruttonManchester Institute of Biotechnology, Department of Chemistry, The University of Manchester, Manchester M1 7DN, U.K.ORCID https://orcid.org/0000-0002-4182-3500
University of Manchester · GB

Funding

Biotechnology and Biological Sciences Research Council BB/L027593/1Biotechnology and Biological Sciences Research Council BB/M000354/1Biotechnology and Biological Sciences Research Council BB/M017702/1
6 · The paper itself

Abstract

Terpenes are the largest class of natural products and are attractive targets in the fuel, fragrance, pharmaceutical, and flavor industries. Harvesting terpenes from natural sources is environmentally intensive and often gives low yields and purities, requiring further downstream processing. Engineered terpene synthases (TSs) offer a solution to these problems, but the low sequence identity and high promiscuity among TSs are major challenges for targeted engineering. Rational design of TSs requires identification of key structural and chemical motifs that steer product outcomes. Producing the sesquiterpenoid 10-

Identifiers

PMID36249875
PMCPMC9552170
OpenAlexW4296691488

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.